Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma with ESR1 gene amplification
Jenny L. Soiffer,
Alexander J. Fife,
Shrikanth S. Gadad,
Javier A. Laurini,
Julia A. Elvin,
Sara S. Isani,
Ken Y. Lin
Affiliations
Jenny L. Soiffer
Albert Einstein College of Medicine / Montefiore Medical Center, Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Bronx, NY, United States; Corresponding author at: 1695 Eastchester Road, Bronx, NY 10461, United States.
Alexander J. Fife
Albert Einstein College of Medicine / Montefiore Medical Center, Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Bronx, NY, United States
Shrikanth S. Gadad
Center of Emphasis in Cancer, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States
Javier A. Laurini
Albert Einstein College of Medicine / Montefiore Medical Center, Department of Pathology, Bronx, NY, United States
Julia A. Elvin
Department of Pathology and Diagnostic Medicine, Foundation Medicine Inc., Cambridge, MA, United States
Sara S. Isani
Albert Einstein College of Medicine / Montefiore Medical Center, Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Bronx, NY, United States
Ken Y. Lin
Albert Einstein College of Medicine / Montefiore Medical Center, Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Bronx, NY, United States
